Are New Alzheimer’s Drugs All They Promise To Be?

Cambridge researchers express skepticism about the effectiveness of new amyloid immunotherapy drugs in significantly reducing Alzheimer’s disease impact, citing challenges such as small effect sizes, high costs, and limited patient eligibility. Credit: SciTechDaily.com Researchers question the impact of amyloid immunotherapy on Alzheimer’s , highlighting the small benefits versus significant risks and costs.

Despite regulatory approval by the FDA, other bodies like the EMA express reservations, reflecting broader concerns about these treatments’ real-world efficacy. Alzheimer’s Immunotherapy Challenges Cambridge researchers have cast doubt on whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the impact of Alzheimer’s disease. Writing in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association , the team from Cambridge Public Health argues that substantial challenges including the risk-benefit ratio, limited eligibility, and high cost of the roll-out will limit any benefits of these treatments.

The Prevalence and Pathology of Alzheimer’s Alzheimer’s disease is often quoted as causing 70% of the 55 million cases of dementia worldwide, though the definition of what constitutes the disease is hotly debated. One characteristic of Alzheimer’s is the build-up of clusters of misfolded proteins, one of these being a form of amyloid, leading to plaques in the brain. The cascade hypothesis, a dominant.